Multi-omic approaches to acute kidney injury and repair
Abstract
The kidney has a remarkable regenerative capacity. In response to ischemic or toxic injury, proximal tubule cells can proliferate to rebuild damaged tubules and restore kidney function. However, severe acute kidney injury (AKI) or recurrent AKI events can lead to maladaptive repair and disease progression from AKI to chronic kidney disease (CKD). The application of single-cell technologies has identified injured proximal tubule cell states weeks after AKI, distinguished by a proinflammatory senescent molecular signature. Epigenetic studies have highlighted dynamic changes in the chromatin landscape of the kidney following AKI and have described key transcription factors linked to the AKI response. The integration of multi-omic technologies opens new possibilities to improve our understanding of AKI and the driving forces behind the AKI-to-CKD transition, with the ultimate goal of designing tailored diagnostic and therapeutic strategies to improve AKI outcomes and prevent kidney disease progression.
Copyright and License
© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Acknowledgement
We apologize to all researchers whose work could not be discussed owing to space limitations. We thank Dr. Pietro E. Cippà for the critical reading of the manuscript. L.M.S. Gerhardt was supported by the German Research Foundation (DFG), Germany with a postdoctoral scholarship (GE 3179/1-1). Work in A.P. McMahon's laboratory is supported by grants from the NIDDK, United States (DK126024, 54364, 126925) and Chan Zuckerberg Initiative, United States (CZIF2019-002430).
Funding
L.M.S. Gerhardt was supported by the German Research Foundation (DFG), Germany with a postdoctoral scholarship (GE 3179/1-1). Work in A.P. McMahon's laboratory is supported by grants from the NIDDK, United States (DK126024, 54364, 126925) and Chan Zuckerberg Initiative, United States (CZIF2019-002430).
Conflict of Interest
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.P.M. is a scientific advisor on kidney-related approaches to human disease for Novartis, eGenesis, Iviva, and Trestle Biotherapeutics.
Files
1-s2.0-S2468451121000842-main.pdf
Files
(953.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f47bcd57300b649bb399260b288e6724
|
953.2 kB | Preview Download |
Additional details
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases
- 126925
- National Institute of Diabetes and Digestive and Kidney Diseases
- 54364
- National Institute of Diabetes and Digestive and Kidney Diseases
- DK126024
- Chan Zuckerberg Initiative (United States)
- CZIF2019-002430
- Deutsche Forschungsgemeinschaft
- GE 3179/1-1
Dates
- Accepted
-
2021-09-07Accepted
- Available
-
2021-09-21Published online
- Available
-
2021-10-16Version of Record